AVDL
Avadel Pharmaceuticals plcNASDAQHealthcare$21.64+0.00%ClosedMarket Cap: $2.12B
As of 2026-04-04
Valuation
P/E (TTM)
—
PEG
—
P/B
21.39
P/S
8.55
EV/EBITDA
205.49
DCF Value
$12.00
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.5%
Operating Margin
1.8%
Net Margin
-0.1%
ROE
-0.3%
ROA
-0.1%
ROIC
0.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $77.5M | 103.9% | $1.9M | $20.0K | $0.00 | — |
| Q2 2025 | $68.1M | 90.7% | $8.9M | $9.7M | $0.10 | — |
| Q1 2025 | $52.5M | 89.4% | $-3.0M | $-4.9M | $-0.05 | — |
| Q4 2024 | $50.4M | 90.5% | $-3.3M | $-5.0M | $-0.05 | — |
| FY 2024 | $169.1M | 91.0% | $-42.4M | $-48.8M | $-0.51 | — |
| Q3 2024 | $50.0M | 87.7% | $-327.0K | $-2.6M | $-0.03 | — |
| Q2 2024 | $41.5M | 93.3% | $-12.7M | $-13.8M | $-0.14 | — |
| Q1 2024 | $27.2M | 94.4% | $-26.0M | $-27.3M | $-0.30 | — |
| Q4 2023 | $19.5M | 96.4% | $-24.9M | $-28.8M | $-0.33 | — |
| FY 2023 | $28.0M | 97.0% | $-137.8M | $-160.3M | $-2.00 | — |
| Q3 2023 | $7.0M | 98.3% | $-35.1M | $-36.3M | $-0.41 | — |
| Q2 2023 | $1.5M | 97.6% | $-49.5M | $-64.4M | $-0.83 | — |